Ori Biotech Raises $30M in Series A Financing

Ori Biotech Ltd, a London, UK-and New Jersey-based cell and gene therapy (CGT) manufacturing company, closed aĀ $30mĀ Series A financing round, bringing total funding to date toĀ $41m.

Ori Biotech

The round was led by Northpond Ventures, alongsideĀ Octopus Ventures, with participation from existing institutional investorsĀ Amadeus Capital Partners,Ā Delin Ventures, andĀ Kindred Capital.

The company intends to use the funds to bring its manufacturing platform to the market.

The Ori platform delivers scalable solutions to flexibly address the critical clinical and commercial manufacturing needs of CGT developers.

Led by Jason C. Foster, CEO, and Dr. Farlan Veraitch, Co-Founder and Chief Scientific Officer, Ori Biotech cell and gene therapy (CGT) manufacturing technology company. Ori has developed a proprietary, flexible manufacturing platform that closes, automates and standardizes manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial-scale manufacturing.

The company has brought together a seasoned board and executive management team with over 100 years of pharmaceutical, cell therapy and venture building experience, including CEOĀ Jason C. FosterĀ (Indivior), CBO Jason Jones (Miltenyi Biotec) andĀ Tom HeathmanĀ (HCATS) alongside industry-leading expert advisors likeĀ Bruce Levine,Ā Annalisa JenkinsĀ andĀ Anthony Davies.



Join the discussion